IN THE NEWS
-
FIRST-HALF 2023 RESULTS - SALES DOWN 13% AND RESILIENT PROFITABILITY
Evry, France, Thursday October 19, 2023, 5:45pm - IntegraGen (FR0010908723 - ALINT - PEA PME eligible), an OncoDNA company specializing in cancer and disease genomics, is... Read More
-
INTEGRAGEN AND BIOASTER SIGN PARTNERSHIP AGREEMENT IN GENOMICS AND TRANSCRIPTOMICS
IntegraGen and BIOASTER have been collaborating for several years on genomic and transcriptomic analyses. Driven by the desire to strengthen this relationship, the two entities have entered into a... Read More
-
INTEGRAGEN SUPPORTS THE ANTOINE LACASSAGNE CENTER IN NICE FOR A LARGE-SCALE RESEARCH PROJECT ON COLORECTAL CANCER PATIENTS
Founded in 1961, the Centre Antoine Lacassagne is one of the 18 Cancer Centers in the UNICANCER network in France. The Center's mission is to... Read More
LATEST NEWS
-
INTEGRAGEN AND BIOASTER SIGN PARTNERSHIP AGREEMENT IN GENOMICS AND TRANSCRIPTOMICS
IntegraGen and BIOASTER have been collaborating for several years on genomic and transcriptomic analyses. Driven by... Read More
-
INTEGRAGEN SUPPORTS THE ANTOINE LACASSAGNE CENTER IN NICE FOR A LARGE-SCALE RESEARCH PROJECT ON COLORECTAL CANCER PATIENTS
Founded in 1961, the Centre Antoine Lacassagne is one of 18 cancer centers... Read More
-
NEW LOOK. NEW PORTFOLIO. NEW OPPORTUNITIES.
FOLLOWING ITS ACQUISITION BY ONCODNA, INTEGRAGEN HAS UNDERGONE A COMPLETE OVERHAUL AND IS NOW... Read More
-
POTENTIAL INVOLVEMENT OF URINARY TRACT INFECTIONS IN THE DEVELOPMENT OF BLADDER CANCER
Uropathogenic E.coli induces DNA damage in the bladder As provider of the whole genome sequencing, IntegraGen... Read More
